Cargando…

Reactor design and selection for effective continuous manufacturing of pharmaceuticals

Pharmaceutical production remains one of the last industries that predominantly uses batch processes, which are inefficient and can cause drug shortages due to the long lead times or quality defects. Consequently, pharmaceutical companies are transitioning away from outdated batch lines, in large pa...

Descripción completa

Detalles Bibliográficos
Autor principal: Hu, Chuntian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130218/
https://www.ncbi.nlm.nih.gov/pubmed/34026279
http://dx.doi.org/10.1007/s41981-021-00164-3
_version_ 1783694469075304448
author Hu, Chuntian
author_facet Hu, Chuntian
author_sort Hu, Chuntian
collection PubMed
description Pharmaceutical production remains one of the last industries that predominantly uses batch processes, which are inefficient and can cause drug shortages due to the long lead times or quality defects. Consequently, pharmaceutical companies are transitioning away from outdated batch lines, in large part motivated by the many advantages of continuous manufacturing (e.g., low cost, quality assurance, shortened lead time). As chemical reactions are fundamental to any drug production process, the selection of reactor and its design are critical to enhanced performance such as improved selectivity and yield. In this article, relevant theories, and models, as well as their required input data are summarized to assist the reader in these tasks, focusing on continuous reactions. Selected examples that describe the application of plug flow reactors (PFRs) and continuous-stirred tank reactors (CSTRs)-in-series within the pharmaceutical industry are provided. Process analytical technologies (PATs), which are important tools that provide real-time in-line continuous monitoring of reactions, are recommended to be considered during the reactor design process (e.g., port design for the PAT probe). Finally, other important points, such as density change caused by thermal expansion or solid precipitation, clogging/fouling, and scaling-up, are discussed. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8130218
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-81302182021-05-18 Reactor design and selection for effective continuous manufacturing of pharmaceuticals Hu, Chuntian J Flow Chem Review Pharmaceutical production remains one of the last industries that predominantly uses batch processes, which are inefficient and can cause drug shortages due to the long lead times or quality defects. Consequently, pharmaceutical companies are transitioning away from outdated batch lines, in large part motivated by the many advantages of continuous manufacturing (e.g., low cost, quality assurance, shortened lead time). As chemical reactions are fundamental to any drug production process, the selection of reactor and its design are critical to enhanced performance such as improved selectivity and yield. In this article, relevant theories, and models, as well as their required input data are summarized to assist the reader in these tasks, focusing on continuous reactions. Selected examples that describe the application of plug flow reactors (PFRs) and continuous-stirred tank reactors (CSTRs)-in-series within the pharmaceutical industry are provided. Process analytical technologies (PATs), which are important tools that provide real-time in-line continuous monitoring of reactions, are recommended to be considered during the reactor design process (e.g., port design for the PAT probe). Finally, other important points, such as density change caused by thermal expansion or solid precipitation, clogging/fouling, and scaling-up, are discussed. GRAPHICAL ABSTRACT: [Image: see text] Springer International Publishing 2021-05-18 2021 /pmc/articles/PMC8130218/ /pubmed/34026279 http://dx.doi.org/10.1007/s41981-021-00164-3 Text en © Akadémiai Kiadó 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Hu, Chuntian
Reactor design and selection for effective continuous manufacturing of pharmaceuticals
title Reactor design and selection for effective continuous manufacturing of pharmaceuticals
title_full Reactor design and selection for effective continuous manufacturing of pharmaceuticals
title_fullStr Reactor design and selection for effective continuous manufacturing of pharmaceuticals
title_full_unstemmed Reactor design and selection for effective continuous manufacturing of pharmaceuticals
title_short Reactor design and selection for effective continuous manufacturing of pharmaceuticals
title_sort reactor design and selection for effective continuous manufacturing of pharmaceuticals
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130218/
https://www.ncbi.nlm.nih.gov/pubmed/34026279
http://dx.doi.org/10.1007/s41981-021-00164-3
work_keys_str_mv AT huchuntian reactordesignandselectionforeffectivecontinuousmanufacturingofpharmaceuticals